Chen Yen-Ting, General Manager of Taiwan Lotte Pharmaceuticals & Biotech Co., Ltd. said that the head office attaches importance to the development of Taiwan's healthcare industry, and hopes to bring new opportunities for head and neck cancer treatment.
Head and neck cancer includes nasopharyngeal cancer, oral cavity cancer, oropharyngeal cancer, laryngeal cancer, etc. In order to overcome cancer, Lotte Pharmaceuticals, which develops precise anti-cancer drugs, has recently set up subsidiaries in Amsterdam, the Netherlands, and Taipei, Taiwan, in the hope of further deepening the cultivation of the European and Asian markets. The company is developing ASP-1929 for the treatment of head and neck cancer and is currently conducting a Phase III clinical trial and will enroll head and neck cancer patients in Taiwan.
ASP-1929 Approved for U.S.-Japan Fast Track Review
ASP-1929 has been approved by the U.S. Food and Drug Administration (FDA) and the Ministry of Health, Labor and Welfare (MHLW) of Japan for Phase III clinical trials for the treatment of recurrent head and neck squamous cell carcinoma. ASP-1929 has entered Phase III clinical trials for the treatment of recurrent squamous cell carcinoma of the head and neck. A further Phase 2 study has been initiated to evaluate the safety of this therapy for the treatment of patients with other cancers.
Delivering safe and effective medicines to fight cancer!
Hiroshi Mikitani, Chairman and CEO of Lotte Pharma, stated that the development and promotion of new anticancer medicines through patented photoimmunotherapy will realize the concept of defeating cancer and providing safe and effective medicines to patients around the world to change and improve their lives.
Recruiting Head and Neck Cancer Patients for Clinical Trials in Taiwan
Chen Yen-Ting, General Manager of Lotte Pharma Biotech Taiwan, said that oral cancer has been ranked among the top 10 cancers in Taiwan, and the mortality rate rankings have been trending forward for the past 10 years, and that the company's key product being developed, ASP-1929, is for the treatment of head and neck cancer. ASP-1929, a key product in the company's development, is used for the treatment of head and neck cancer, and is currently undergoing phase III clinical trials. Therefore, the Taiwan team is currently recruiting patients for clinical trials in Taiwan, and hopes to introduce innovative treatment methods and enhance the effectiveness of patient care in Taiwan as soon as possible in the future.
Taipei office to expand into Asia
Lotte Pharma said the Amsterdam office will be the main office in Europe, and the German office, which will begin operations in 2016, will serve as a research and development and manufacturing base for photo-immunotherapy devices. The Taipei office, which is part of the Japan headquarters, will further expand into Asia and will be responsible for the promotion of therapeutic drugs after they are launched. The establishment of these two offices is a key step in enhancing LottePharma's R&D capabilities and global visibility, as well as assisting LottePharma's ongoing global Phase III clinical trials and future studies.
LINE@ ID:@ Subscribe to the Healthy Love LOHAS AV channel for easier reading of health knowledge : /beauty/article/42509 Keywords: Hiroshi Mikitani, Head and Neck Cancer, ASP-1929, Anti-cancer Drugs, Cancer, Lotte Pharmaceuticals